Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KP-001 in Venous Malformations, Lymphatic Malformations, or KTS/CLOVES Syndrome
NCT07285005Phase 3Recruiting
- Sponsor
- Kaken Pharmaceutical Co., Ltd.
- Start
- May 2026
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in venous malformation (VM), Lymphatic Malformation (LM), Klippel-Trenaunay syndrome (KTS) and 1 more comparing KP-001 with placebo (2 arms). Primary endpoint: Ratio of volume of target lesions based on MRI at 24 weeks. Started May 2026; status: recruiting.
02
Drugs
KP001
03
Conditions
venous malformation (VM)Lymphatic Malformation (LM)Klippel-Trenaunay syndrome (KTS)Congenital Lipomatous Overgrowth, Vascular Malformations, Epidermal Nevi, and Spinal/Skeletal Anomalies (CLOVES)
Beyond the preview
Go deeper on NCT07285005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07285005.